Table 3.
Therapeutics targeting the OCSCs
| Agent | Target | Mechanism of action | Study phase |
|---|---|---|---|
| DAPT | Notch pathway | GSIs | In vitro |
| WFA | Notch pathway | Notch1 inhibitor | Both in vitro and in vivo |
| Eugenol | Notch pathway | Notch-Hes1 inhibitor | Both in vitro and in vivo |
| TF3 | Wnt/β-Catenin | β-Catenin down-regulator | In vitro |
| Ginsenoside-Rb1 metabolite compound K | Wnt/β-Catenin | β-Catenin down-regulator | Both in vitro and in vivo |
| Calcitriol | Wnt/β-Catenin | VDR down-regulator | Clinical trial phase 1 |
| N-t-boc-Daidzein | PI3K/Akt/mTOR | Akt/mTOR down-regulator | In vitro |
| DFOG | PI3K/Akt/mTOR | FOXM1 inhibitor | In vitro |
| EriB | NF-κB | Nuclear p54 inhibitor | In vitro |
| 3PO | NF-κB | PFKFB3 inhibitor | In vitro |
| PFK158 | NF-κB | PFKFB3 inhibitor | Clinical trial phase 1 |
| VP | Hippo | YAP inhibitor | Both in vitro and in vivo |
| dCD133KDEL | CD133 | CD133 monoclonal antibody | Both in vitro and in vivo |
| ATRA | ALDH | ALDH1 inhibitor | Both in vitro and in vivo |
| DDB2 | ALDH | ALDH1a1 inhibitor | Both in vitro and in vivo |
| Metformin | multiple | CD44 down-regulator | Clinical trial phase 2 |
| Salinomycin | multiple | Apoptotic proteins promoter | Both in vitro and in vivo |
| CCBs | AKT/ERK pathway | Apoptotic proteins promoter | In vitro |